Clinical Trials Market in India

India has emerged as a strong base for clinical trials in recent times. Due to the multitude of benefits it offers, the country is fast growing as a centre for conducting clinical trials for many international companies. So It has launched its research report called “Booming Clinical Trials Market in India” to give first-hand information on the Indian clinical trials market. It investigates the key competitive advantages/disadvantages India has when it comes to conducting clinical trials in the country. The report also does a through study of the key factors which evaluate the country’s clinical trials, such as patient pool, patient recruitment, cost, time, government regulations, intellectual property, human resources, infrastructure and ethical issues.

India, with its huge patient base, low cost advantage, completion of clinical trials on time, improving infrastructure, and with a strong government support is witnessing a double digit growth in its clinical trials market. All major pharmaceutical companies and Clinical Research Organizations (CROs) have already started conducting their clinical trials in India, and with improving infrastructure, industry friendly regulations and trained workforce, the growth is only likely to increase in future.

However, to achieve its goal of becoming a global hub of clinical trials, the country will have to overcome challenges like unethical trials, delay in trial approval, inappropriate protection of clinical data, and lack of Good Clinical Practice (GCP ) certified sites and investigators.

Some Key Findings

• Indian clinical trials market is expected to grow at a CAGR of nearly 36% between 2006 and 2011 to register revenues worth US$ 546 Million in future.
• One of the biggest advantages of conducting clinical trials in India is the availability of a large patient pool that can be recruited at much shorter time then it takes to recruit patients in the west.
• India by 2011 will be conducting more than 15% of the total global clinical trials.
• India presently lacks in GCP trained investigators (which are less than 1000). Their demand is projected to reach between 3000 and 6000 by 2010.
• India does not provide “Data Exclusivity” in clinical trials unlike the US and EU members.
• The salaries of a clinical data specialist and Medical writer in India are around 15% and 9% respectively of what they get in the US.
• The clinical trials market will drive the growth of the Diagnostics and Pathology Industry in India.